On the stock market since 2021, it operates in the world of health and science. It has 65 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 37% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $37.9M a year. A small number, but proof the product has real buyers.
A loss of $57.2M against $37.9M in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 57 sells against just 9 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 30% above the average analyst price target.
On our five-subject report card, TSVT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TSVT is a high-risk stock — not yet profitable, and its future rides on its product catching on.